Deep Origin, BioAge Launch Multi-Target AI-Driven Drug Discovery Collab
Read Full Article on Contract Pharma
Contract Pharma covers Deep Origin's multi-target AI-driven drug discovery collaboration with BioAge Labs, which reached its first milestone when BioAge's wet lab validated hits Deep Origin identified against a novel target in under three months.
Contract Pharma reports that Deep Origin and BioAge Labs have launched a multi-target, AI-driven drug discovery collaboration that has already hit its first milestone: BioAge’s wet lab validated novel small-molecule hits that Deep Origin identified computationally against a novel BioAge target. The article notes that the partnership pairs hybrid AI and physics-based models with BioAge’s focus on novel targets, that Deep Origin delivered several structurally distinct hits against the first target in under three months, and that BioAge is now advancing that target into hit-to-lead optimization. Deep Origin is eligible for success-based milestone payments.
The piece quotes Deep Origin co-founder and CEO Michael Antonov on BioAge’s human-data-derived targets, many with little known chemistry, as “exactly the problem our virtual screening was built to solve,” and BioAge co-founder and CEO Kristen Fortney, Ph.D., on the platform delivering high-quality chemical matter against a novel target in just months.
For our own announcement, see Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target.
